全文获取类型
收费全文 | 567篇 |
免费 | 44篇 |
国内免费 | 3篇 |
专业分类
儿科学 | 35篇 |
妇产科学 | 6篇 |
基础医学 | 25篇 |
临床医学 | 197篇 |
内科学 | 138篇 |
皮肤病学 | 15篇 |
神经病学 | 39篇 |
特种医学 | 3篇 |
外科学 | 108篇 |
综合类 | 25篇 |
预防医学 | 5篇 |
眼科学 | 2篇 |
药学 | 12篇 |
中国医学 | 3篇 |
肿瘤学 | 1篇 |
出版年
2023年 | 17篇 |
2022年 | 7篇 |
2021年 | 19篇 |
2020年 | 10篇 |
2019年 | 17篇 |
2018年 | 15篇 |
2017年 | 16篇 |
2016年 | 17篇 |
2015年 | 15篇 |
2014年 | 20篇 |
2013年 | 40篇 |
2012年 | 17篇 |
2011年 | 26篇 |
2010年 | 18篇 |
2009年 | 13篇 |
2008年 | 27篇 |
2007年 | 23篇 |
2006年 | 21篇 |
2005年 | 23篇 |
2004年 | 18篇 |
2003年 | 22篇 |
2002年 | 14篇 |
2001年 | 17篇 |
2000年 | 16篇 |
1999年 | 19篇 |
1998年 | 13篇 |
1997年 | 11篇 |
1996年 | 9篇 |
1995年 | 10篇 |
1994年 | 5篇 |
1993年 | 3篇 |
1992年 | 9篇 |
1991年 | 9篇 |
1990年 | 3篇 |
1989年 | 6篇 |
1988年 | 8篇 |
1987年 | 10篇 |
1986年 | 7篇 |
1985年 | 8篇 |
1984年 | 9篇 |
1983年 | 5篇 |
1982年 | 9篇 |
1981年 | 4篇 |
1980年 | 4篇 |
1979年 | 3篇 |
1978年 | 2篇 |
排序方式: 共有614条查询结果,搜索用时 140 毫秒
1.
2.
Introduction – Toxic phytanic acid concentrations in patients with Refsum's disease can be reduced by plasma separation, performed either as plasmapheresis, or as cascade filtration. The latter procedure is as efficient and safe as plasmapheresis, and eliminates the need for albumin replacement. This study investigates the loss of immunoglobulins associated with the procedure. Material and methods — Immunoglobulin- and phytanic acid serum concentrations before and after cascade filtration (n=16) were measured in a patient with Refsum's disease and their removal determined. Filters with sieving coefficients for immunoglobulin G of 70% and 30% were compared with each other and with historical data on plasmapheresis. Results — While differences in immunoglobulin M loss are negligible, the loss of immunoglobulin G in cascade filtration is significantly less than that reported for plasmapheresis and depends upon the pore size of the employed filters. The loss is least with larger pore size, but this advantage becomes statistically insignificant if immunoglobulin G loss is related to the lesser decrease in phytanic acid concentration that was achieved simultaneously in this study. Conclusion — Unless transplantation of a-hydroxylase containing tissue can be established as treatment for Refsum's disease, cascade filtration appears to be the treatment of choice in order to avoid loss of albumin and to reduce the loss of immunoglobulin G. 相似文献
3.
4.
BACKGROUND: It is suggested that the highly cation-charged fraction of the IgG and IgG3 subclasses may play a pathogenic role in lupus nephritis. In contrast, immunoadsorbent therapy using a sodium dextransulfate fixed cellulose gel column-low invasive selective immunoadsorbent apheresis therapy (SDSC-IAT) has been applied to lupus nephritis with favorable results. However, elimination using pathogenic IgG by SDSC-IAT has never been investigated. METHOD: Two patients with diffuse proliferative lupus nephritis were treated using SDSC-IAT concomitant with immunosuppressive therapy. The eluates from the SDSC, and the patients' serum obtained before and just after SDSC-IAT were subjected to an IgG charge analysis using isoelectric focusing and immunoblotting, and also to laser nephelometry assay, which is used for measuring IgG subclass concentration. Indirect immunofluorescence staining was performed to detect IgG subclass deposition in the glomerulus. RESULTS: Both of the patients had an immediate decrease in anti-double-strand DNA antibody and in the circulating immune complex with a following clinical improvement. Repeated biopsies demonstrated improvement of glomerular lesions with a marked reduction of IgG and C3 deposition. The IgG of the SDSC eluates consisted of highly cation charged (isoelectric points: 9-10) fractions. In addition, IgG3 was specifically removed from the patients' serum using an SDSC among the IgG subclasses. The subclass of deposited IgG in the glomeruli showed IgG3 predominance. CONCLUSION: SDSC-IAT specifically removed the highly cation charged fractions of IgG and IgG3 from the patients' serum and the elimination of these fractions may have resulted in clinical improvement. 相似文献
5.
不同疗法对格林-巴利综合征短期疗效的评估 总被引:1,自引:0,他引:1
目的评估不同治疗方法对格林-巴利综合征的短期疗效。方法回顾性收集应用血浆交换、静脉用免疫球蛋白和激素不同治疗的45例格林-巴利综合征住院患者的临床资料。结果接受单膜血浆交换或双膜血浆吸附治疗的24例患者和16例接受免疫球蛋白治疗中的11例患者,临床表现迅速改善。在免疫球蛋白治疗组中有5例患者和接受甲基强的松龙冲击治疗的全部5例患者,临床改善不明显。结论血浆交换或吸附的治疗效果最好,免疫球蛋白的治疗作用次之,激素治疗效果不明显。 相似文献
6.
Andrea A. Zachary Robert A. Montgomery Mary S. Leffell 《Clinical and Applied Immunology Reviews》2005,5(6):373
Sensitization to antigens of the HLA and ABO system has been the biggest barrier to access in renal transplantation and, increasingly, in transplantation of other organs. Additionally, antibody to donor antigens has been shown to result in injury to the graft ranging from catastrophic, irreversible hyperacute rejection to the slower, more insidious, chronic form of rejection. The problem of access has been recognized globally and has been the incentive for measures to overcome the disadvantage experienced by the sensitized patient. However, early attempts to reduce sensitization achieved only transient success. Newer immunosuppressive agents that affect B-cell function or viability have permitted the development of treatment protocols to eliminate and, potentially, downregulate donor-specific antibodies. The use of these protocols has achieved successful transplants that were HLA and/or ABO incompatible prior to treatment and, as such, has provided some patients with their only opportunity for transplantation. 相似文献
7.
Tang-Liu Diane D. -S. Liu Sandra 《Journal of pharmacokinetics and pharmacodynamics》1987,15(4):387-397
The differences in flurbiprofen disposition in the aqueous humor and the plasma were examined after systemic doses. Steady state plasma concentrations of flurbiprofen (20–60 g/mL) were achieved via intravenous infusion to albino rabbits. Flurbiprofen demonstrated linear systemic kinetics throughout the dosing range, with constant body clearance and unbound fraction in plasma. At steady state, aqueous humor drug concentrations depended on the corresponding plasma drug concentration. Two clearance terms—CLso, the systemic clearance to ocular tissues, and CLos, the ocular clearance to systemic circulation—were used. After systemic doses, the drug concentration in the aqueous humor was related to that in the plasma as well as to the ratio of these two clearances. Flurbiprofen was extensively bound to plasma proteins and showed limited ocular distribution; its CLso to CLso tratio was very small. Thus, the concentration of flurbiprofen in the aqueous humor after systemic doses was lower than that obtained after ophthalmic doses. A plasmapheresis technique was utilized to lower the plasma protein concentrations to 60% of normal levels. As a consequence, flurbiprofen demonstrated reduced aqueous humor protein concentrations, increased unbound fractions in the plasma and the aqueous humor, elevated aqueous humor drug concentrations, and elevated total body clearance. The unbound body clearance stayed unchanged. Our study indicated that a drug should present a significant CLso/CLos ratio in order to achieve therapeutic concentrations in the eye via systemic doses. The drug-protein binding kinetics can be different between the plasma and the aqueous humor circulations. Because the ocular compariment is very small compared to the overall systemic distribution of flurbiprofen, it has little effect on the steady state systemic concentrations. 相似文献
8.
Julien Guihaire Serena D'Avino Francois Stephan Martin Kloeckner Ngoc Tram To Agathe Potier Maïra Gaillard Ramzi Ramadan Jean‐Luc Taupin Jerome Le Pavec Philippe Deleuze 《Clinical transplantation》2021,35(1):e14146
Antihuman leukocyte antigen (HLA) antibodies restrict the access to cardiac allografts. Desensitization therapy is a major challenge in patients with cardiogenic shock waiting for urgent heart transplantation (HT). We retrospectively reviewed six patients (mean age of 37.5 years [16–70]) who underwent plasmapheresis (PP) under extracorporeal membrane oxygenation (ECMO) before transplant between January 2017 and September 2018. The average duration of follow‐up was 25 months [20–32]. Mean fluorescence intensity (MFI) of HLA‐specific antibodies was reported as follows: score 4 for MFI < 1000, score 6 for 1000 < MFI < 3000 and score 8 for MFI > 3000. The mean duration of ECMO support was 29 days [1–74] and 6.8 [1–29] PP sessions were performed per patient before transplant. The mean number of HLA‐specific antibodies before HT was 9.6 for score 6 [4–13] and 5.8 for score 8 [1–12]. Four patients had major complications after transplantation (2 hemorrhagic shocks, 5 infectious events). Mean MFI reduction rate was 94% [79–100] for Class I and 44.2% for Class II [0–83]. Hospital survival was 100%, and early antibody‐mediated rejection was diagnosed in one patient at 7 days after HT. Plasmapheresis under ECMO support was associated with favorable early outcomes in highly sensitized candidates for urgent heart transplantation. 相似文献
9.
Hypotension is an uncommon complication of procedures involving extracorporeal circulation, including plasmapheresis. From November 1993 to March 1999, we treated 139 patients who underwent a total of 1,137 sessions of double filtration plasmapheresis (DFP). Hypotension was defined as a systolic blood pressure (BP) < 80 mm Hg or any decrease of systolic BP with systemic reactions. A total of 17 (1.5%) episodes of hypotension were documented in 15 patients during the study period. Hypotensive episodes occurred in 2.3% of patients with inflammatory neuropathy, 1.2% of patients with myasthenia gravis, and 1.2% of patients with all other medical diseases. Involvement of the autonomic nerve system (ANS) and a low baseline BP were associated with the occurrence of hypotension. Eight (47%) of 17 episodes were symptomatic and 2 were complicated with seizure. Patients with symptomatic hypotension had a higher level of systolic BP prior to DFP and a larger drop of systolic BP and pulse rate during hypotensive attacks compared to asymptomatic patients. Most hypotensive episodes were resolved briefly after intravenous infusion of saline within 30 min. Eight (47%) of the hypotensive episodes occurred during the first session of DFP treatment. Twelve (71%) of 17 episodes occurred during the last half period of treatment; 6 of them were noted during the terminating stage of DFP. In conclusion, in this series plasmapheresis-related hypotension occurred in 1.5% of DFP sessions and had a higher prevalence in patients with ANS instability and low BP. Extra caution in monitoring BP during DFP therapy is warranted in these vulnerable patients, especially during the termination phase of the first DFP session. 相似文献
10.
Comparison between double-filtration plasmapheresis and immunoadsorption plasmapheresis in the treatment of patients with myasthenia gravis 总被引:1,自引:0,他引:1
Two techniques for plasmapheresis are used in the treatment of myasthenia gravis (MG): immunoadsorption (IA) and double filtration
(DR). This controlled study evaluated the differences between these techniques in clinical effects and serological changes.
Five patients with generalized MG (clinical states IIb and III) were enrolled; each patient received IA and DF plasmapheresis
on separate occasions. Immunosorba TR-350 with an affinity to acetylcholine receptor antibodies (AchRAb) was used for IA,
while Evaflux 4A was used as the plasma fractionator for DF. Each course of treatment consisted of five sessions of apheresis.
MG score, titers of AchRAb, immunoglobulins (IG), and plasma biochemistry were assessed by blinded examiners before and immediately
after the entire course of treatment. Both treatments effectively ameliorated symptoms of MG. There were no significant changes
in MG score between the two groups (IA vs. DF: 2.2 vs. 2.6, P>0.5). IA had a higher clearance rate of AchRAb than DF (66 % vs. 54 %, P<0.05), while DF removed more IgA (72 % vs. 21 %, P< 0.05) and IgM (89 % vs. 57 %, P<0.01) than did IA. Although IA removed AchRAb more effectively than DF, the clinical effects between these two treatments
were similar. The titers of AchRAb cannot reflect the clinical severity. Some circulating factors other than AchRAb may contribute
to the pathogenesis of MG.
Received: 10 September 1999, Received in revised form: 7 February 2000, Accepted: 24 February 2000 相似文献